This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Marta Gwinn, MD, MPH; Joanne V. Mei, PhD; Catherine L. Spruill; Trudy L. Dobbs; W. Harry Hannon, PhD
Centers for Disease Control and Prevention Atlanta, Ga

Marlene LaLota, MPH
Florida Department of Health and Rehabilitative Services Tallahassee

JAMA. 1997;277(4):299.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In August 1994, the US Public Health Service issued recommendations for administering zidovudine to pregnant women infected with the human immunodeficiency virus (HIV) and their newborns to reduce the risk of perinatal HIV transmission.¹ We conducted an anonymous, population-based study to estimate the proportion of HIV-infected women giving birth in Florida from October 1994 through March 1995 who received perinatal treatment with zidovudine. We used a modified radioimmunoassay for serum zidovudine to test dried-blood specimens that had been collected from newborns for routine metabolic screening. These specimens had been tested anonymously for maternal HIV antibody as part of a nationwide HIV serosurvey conducted under an existing protocol that had institutional review board approval. Performance characteristics of the modified assay are described elsewhere,² and studies are now in progress to develop a confirmatory test. The metabolism of zidovudine is delayed in neonates, resulting in . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?